Topics

Foundation Medicine touts concordance ahead of FDA ruling on liquid biopsy test

08:05 EST 16 Jan 2020 | MedCity News

lab test, LDTs

The company filed for FDA approval of the FoundationOne Liquid test at the end of December. Data from a clinical trial presented at an October conference showed the test had a strong ability to detect a genetic driver mutation in lung cancer.

Original Article: Foundation Medicine touts concordance ahead of FDA ruling on liquid biopsy test

NEXT ARTICLE

More From BioPortfolio on "Foundation Medicine touts concordance ahead of FDA ruling on liquid biopsy test"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...